eFFECTOR Therapeutics
EFTRPhase 2Market Cap
$941
Focus
Biotech
EFTR · Stock Price
USD 0.00103.50 (-100.00%)
Historical price data
Pipeline Snapshot
1313 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib | Endometrial Cancer | Phase 2 |
| Tomivosertib (eFT-508) | Solid Tumors | Phase 2 |
| eFT508 | Castrate-resistant Prostate Cancer (CRPC) | Phase 2 |
| eFT508 | Triple Negative Breast Cancer | Phase 2 |
| eFT508 + Avelumab | Microsatellite Stable Relapsed or Refractory Colorectal Cancer | Phase 2 |
Funding History
3Total raised: $138M
IPO$60MUndisclosedJul 22, 2021
Series B$33MThe Column GroupJun 15, 2015
Series A$45MThird Rock VenturesJun 15, 2013
Company Info
TypePublic
LocationUnited States
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile